Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.937555
Keywords
alpha-synuclein; diet; gut microbiota; microbiota-targeted therapy; Parkinson's disease
Categories
Funding
- Key R&D Program of Zhejiang [2022C03060]
- Lishui & ZJU Cooperation Project [2018zdhz07]
- S&T Major Project of Lishui [2017YSKZ-01, 2017ZDYF04, 2017ZDYF15]
- National Natural Science Foundation of China [81771724, 31700800, 81790631]
- Zhejiang Basic Public Welfare Research Project [LGF20H090016]
- Research Project of Jinan Microecological Biomedicine Shandong Laboratory [JNL-2022033C]
- Taishan Scholar Foundation of Shandong Province [tsqn202103119]
- Nutrition and Care of Maternal & Child Research Fund Project of Guangzhou Biostime Institute of Nutrition Care [2019BINCMCF045]
- National S&T Major Project of China [2018YFC2000500]
- Foundation of China's State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
Ask authors/readers for more resources
Parkinson's disease is a common neurodegenerative disease characterized by motor dysfunction. Gut dysbiosis is involved in the development and progression of PD, and the gut microbiota can be considered as a potential diagnostic and therapeutic target. Gut dysbiosis influences the progression and onset of PD by increasing intestinal permeability, aggravating neuroinflammation, aggregating abnormal levels of alpha-synuclein fibrils, increasing oxidative stress, and decreasing neurotransmitter production.
Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by motor dysfunction. Growing evidence has demonstrated that gut dysbiosis is involved in the occurrence, development and progression of PD. Numerous clinical trials have identified the characteristics of the changed gut microbiota profiles, and preclinical studies in PD animal models have indicated that gut dysbiosis can influence the progression and onset of PD via increasing intestinal permeability, aggravating neuroinflammation, aggregating abnormal levels of alpha-synuclein fibrils, increasing oxidative stress, and decreasing neurotransmitter production. The gut microbiota can be considered promising diagnostic and therapeutic targets for PD, which can be regulated by probiotics, psychobiotics, prebiotics, synbiotics, postbiotics, fecal microbiota transplantation, diet modifications, and Chinese medicine. This review summarizes the recent studies in PD-associated gut microbiota profiles and functions, the potential roles, and mechanisms of gut microbiota in PD, and gut microbiota-targeted interventions for PD. Deciphering the underlying roles and mechanisms of the PD-associated gut microbiota will help interpret the pathogenesis of PD from new perspectives and elucidate novel therapeutic strategies for PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available